HOME >> BIOLOGY >> NEWS
Study suggests cell-cycle triggers might be cancer drug targets

BOSTON--In an experiment that appears to refute current theory, Dana-Farber Cancer Institute scientists have found that removing three key proteins believed essential to cell division and growth had little impact on normal tissue development of a mouse embryo. These same proteins, when overly active, have been linked to cancer cell proliferation.

With one significant exception, the absence of proteins called cyclin D1, D2, and D3 seemed to have no deleterious effect on development of the tissues and organs of laboratory mouse embryos. "D-type cyclins" are molecules that sense growth signals from the cell's environment and, when appropriate, switch on cell division and growth. But when the system is faulty, the cyclins over-respond to the growth signals and can cause cancerous growth. The discovery that these proteins aren't indispensable lends encouragement to an idea that blocking overactive cyclins could halt the growth of cancer.

In the Aug. 20 issue of Cell, lead author Katarzyna Kozar, MD, and senior author Peter Sicinski, MD, PhD, report on developing the first mouse embryos to date in which all three D-type cyclins were absent or "knocked out." It had been thought that at least one cyclin was required for an embryo to be viable and its tissues to form normally. Yet the "triple-knockout" mouse embryos followed a normal course of cell division and proliferation until as late as 13.5 days, when most tissues and organs are already formed. A typical mouse pregnancy last 18 days.

(In a companion paper in Cell, researchers from Spain report similar findings involving protein kinases called CDK4 and CDK6, which are molecular partners of the D-cyclins. Embryonic mice with both CDK molecules knocked out had normal tissue development as well.)

The unexpectedly viable embryos contradict theory and previous laboratory experiments. The only abnormality in the triple knockout mice was a deficiency of blood-forming cells, causing them to be pa
'"/>

Contact: Bill Schaller
william_schaller@dfci.harvard.edu
617-632-5357
Dana-Farber Cancer Institute
19-Aug-2004


Page: 1 2 3

Related biology news :

1. Study: Emission of smog ingredients from trees is increasing rapidly
2. Study explores gene transfer to modify underlying course of Alzheimers disease
3. Study reveals why eyes in some paintings seem to follow viewers
4. Study by Israeli scientists provides insight on DNA code
5. Study reveals first genetic step necessary for prostate cancer growth
6. Study of flu patients reveals virus outsmarting key drug
7. Study in Science reveals recreational fishing takes big bite of ocean catch
8. Study narrows search for genes placing men at increased risk for prostate cancer
9. Study links high carbohydrate diet to increased breast cancer risk
10. Study explains spatial orientation differences between sexes
11. Study suggests humans can speed evolution

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/7/2019)... ... 2019 , ... R3 Stem Cell is now offering its comprehensive Online ... code to use during checkout is FIFTYOFF and applies to both the one month ... regenerative therapies with over 12,000 successful stem cell procedures performed nationwide. A couple years ...
(Date:11/5/2019)... ... November 05, 2019 , ... ... for drugs, biologics, gene therapies, and consumer health products, today announced it will ... Sofia, Barcelona, Spain on Nov. 12 – 14, 2019. , On Wednesday, Nov. ...
(Date:10/30/2019)... ... October 29, 2019 , ... LGC Maine ... ATELLICA® analyzers, Order Numbers 701sa & 704sa. The kits, in a human-urine matrix, ... UUN. , Each VALIDATE® kit, liquid, ready-to-use, and prepared using the CLSI EP06-A ...
Breaking Biology News(10 mins):
(Date:11/6/2019)... , ... November 06, 2019 , ... ... through off-the-record collaboration and dialogue, today announces its East/West CEO conference ... in San Francisco. , Kicking off the week of the J.P. ...
(Date:11/5/2019)... , ... November 05, 2019 , ... ... announced it has received CE Mark for its Fusion Bx 2.0 prostate fusion ... and user-friendly interface, the Fusion Bx 2.0 will give urologists across Europe the ...
(Date:11/2/2019)... TORONTO (PRWEB) , ... October 31, 2019 , ... ... are not always used to communicating with each other: study managers, principal investigators, ... cause misunderstandings if a party is not informed of the latest data, potentially ...
(Date:11/2/2019)... ... October 31, 2019 , ... drug360 graph, ... pioneer tellic. drug360 brings tellic’s expertise in biomedical language processing and machine ... quickly uncover relationships between genes, diseases, variants, phenotypes, and other biomedical entities. ...
Breaking Biology Technology:
Cached News: